Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis and monitoring. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly colorectal cancer screening InSure¨ FITª assay, a fecal immunochemical test that detects blood in the stool. InSure¨ FITª is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Building on an established history in the field of colorectal screening and diagnosis, Clinical Genomics developed and launched COLVERAª, a blood-based circulating tumor DNA (ctDNA) test for colorectal cancer recurrence monitoring that detects two methylated genes associated with colorectal cancer. Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.